Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks’ Azymetric™ Platform into Preclinical Development

Tuesday, September 19, 2017 1 min read

Key Takeaway: Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks’ Azymetric™ Platform into Preclinical Development

Full Press Release Details

Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks’ Azymetric™ Platform into Preclinical Development.